Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/11/2019
SIETES contiene 92834 citas

 
 
 1 a 20 de 35 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Caughey GE, Gabb GM, Ronson S, Ward M, Beukelman T, Hill CL, Limaye V. Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102883]
2. Cita con resumen
Ezquerra Pérez G, Martín de la Nava MA, Álvarez-Cienfuegos A, Montaño Barrientos A, Baquero Barroso MJ, Rubio Núñez PL, Gómez Santana MC, Gavilán Moral E, Candela Marroquín E, Sánchez Robles GA. Revisión GRADE de estatinas en población con = 90% en prevención primaria cardiovascular. Sección 3: Efectos adversos. II. Miopatías.. Grupo Evalmed-GRADE 2016:21 de enero. [Ref.ID 99983]
3.
Prasad V. Statins, primary prevention, and overall mortality. Ann Intern Med 2014;160:867-9. [Ref.ID 97767]
4. Cita con resumen
Joy TR, Monjed A, Zou GY, Hegele RA, McDonald ChG, Mahon JL. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 2014;160:301-10. [Ref.ID 97263]
5. Cita con resumen
Ebrahim S, Taylor FC, Brindle P. Statins for the primary prevention of cardiovascular disease. BMJ 2014;348:g280. [Ref.ID 97254]
6. Cita con resumen
Sherman RE, Li J, Shapley S, Robb M, Woodcock J. Expediting drug development - The FDA's new "breakthrough therapy" designation. N Engl J Med 2013;369:1877-80. [Ref.ID 96536]
8.Tiene citas relacionadas
Brotherton JML. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013;347:10. [Ref.ID 96427]
9.
Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33:171-87. [Ref.ID 88049]
10. Cita con resumen
Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med 2010;362:564-5. [Ref.ID 87848]
11.Tiene citas relacionadas
Phillips PS. Balancing randomized trials with anecdote. Ann Intern Med 2009;150:885-6. [Ref.ID 86262]
12.Tiene citas relacionadas
Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68. [Ref.ID 86261]
13. Cita con resumen
Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109. [Ref.ID 84984]
14. Cita con resumen
Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008;337:1159-62. [Ref.ID 84542]
15. Cita con resumen
16.
Bielsa S, Madroñero AB, Grau JM, Porcel JM. Miositis con cuerpos de inclusión asociada a esclerosis sistémica. Med Clin (Barc) 2007;128:278. [Ref.ID 79376]
17. Cita con resumen
McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-43. [Ref.ID 79332]
18.Enlace a cita original
Anónimo. Ezetimibe. Reports of muscular disorders. New Zealand. WHO Pharmaceuticals Newsletter 2006;6:4. [Ref.ID 79109]
19.
Clark DWJ, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?. Eur J Clin Pharmacol 2006;62:473-9. [Ref.ID 77518]
20.
Anónimo. Ezetimibe and muscle disorders. Australia. WHO Drug Information 2005;19:212. [Ref.ID 75408]
Seleccionar todas
 
 1 a 20 de 35 siguiente >>